zuclopenthixole

Zuclopenthixole is a first-generation (typical) antipsychotic of the thioxanthene class used primarily for the treatment of schizophrenia and other psychoses. It is available in several formulations including oral tablets (zuclopenthixole dihydrochloride), short-acting intramuscular injection (zuclopenthixole acetate), and long-acting depot injection (zuclopenthixole decanoate). The drug acts mainly as an antagonist at dopamine D1 and D2 receptors but also has high affinity for alpha1-adrenergic and 5-HT2 serotonin receptors. It has weaker activity at histamine H1 receptors and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors. Zuclopenthixole is used to manage positive symptoms of schizophrenia such as hallucinations and delusions; it may also be used in acute mania associated with bipolar disorder or to control agitation in psychotic patients[2][4][5][6]. The drug was developed by Lundbeck Pharmaceuticals[6].

Brand names

ClopixolClopixol AcuphaseClopixol ConcentrateClopixol DepotCisordinolCisordinol DepotCisordinol-Acutard

Other names

zuclopenthixole dihydrochloridezuclopenthixole acetatezuclopenthixole decanoate